Insulet Stock Performance
PODD Stock | USD 168.74 2.48 1.49% |
The company retains a Market Volatility (i.e., Beta) of 1.31, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Insulet will likely underperform. Insulet has an expected return of -0.3%. Please make sure to check out Insulet daily balance of power, and the relationship between the skewness and day typical price , to decide if Insulet performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Insulet has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (3.73) | Five Day Return (6.40) | Year To Date Return (20.49) | Ten Year Return 286.11 | All Time Return 941.73 |
1 | Disposition of 104 shares by Eric Benjamin of Insulet at 191.01 subject to Rule 16b-3 | 02/20/2024 |
2 | Is It Too Late To Consider Buying Insulet Corporation | 02/22/2024 |
3 | Down -15.31 percent in 4 Weeks, Heres Why You Should You Buy the Dip in Insulet | 02/27/2024 |
4 | Acquisition by Eric Benjamin of 4351 shares of Insulet subject to Rule 16b-3 | 02/29/2024 |
5 | Insulet to Present Results from First Omnipod 5 Randomized Controlled Trial at the 17th International Conference on Advanced Technologies Treatments for Diabete... | 03/05/2024 |
6 | Drug Delivery Devices Market Set to Skyrocket to US90.2 Bn by 2033, Fairfield Market Research Predicts a CAGR of 6.2 | 03/18/2024 |
7 | Insulet Appoints Ana Maria Chadwick as Chief Financial Officer | 03/20/2024 |
8 | Modular Medical Announces Steve Gemmell as New Vice President of Engineering | 03/26/2024 |
9 | Investors Will Want Insulets Growth In ROCE To Persist | 03/28/2024 |
10 | Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 | 04/03/2024 |
11 | Citis value focus list of small and mid-caps | 04/08/2024 |
12 | Will Insulet Beat Estimates Again in Its Next Earnings Report | 04/12/2024 |
13 | Abbott Q1 Earnings Beat Estimates, Margins Contract | 04/17/2024 |
Begin Period Cash Flow | 623.9 M |
Insulet |
Insulet Relative Risk vs. Return Landscape
If you would invest 20,446 in Insulet on January 19, 2024 and sell it today you would lose (3,820) from holding Insulet or give up 18.68% of portfolio value over 90 days. Insulet is currently does not generate positive expected returns and assumes 2.3812% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Insulet, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Insulet Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Insulet's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Insulet, and traders can use it to determine the average amount a Insulet's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1258
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | PODD |
Estimated Market Risk
2.38 actual daily | 21 79% of assets are more volatile |
Expected Return
-0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Insulet is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Insulet by adding Insulet to a well-diversified portfolio.
Insulet Fundamentals Growth
Insulet Stock prices reflect investors' perceptions of the future prospects and financial health of Insulet, and Insulet fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Insulet Stock performance.
Return On Equity | 0.34 | ||||
Return On Asset | 0.0609 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.26 % | ||||
Current Valuation | 12.91 B | ||||
Shares Outstanding | 70.02 M | ||||
Price To Book | 16.75 X | ||||
Price To Sales | 7.23 X | ||||
Revenue | 1.7 B | ||||
Gross Profit | 805.6 M | ||||
EBITDA | 220 M | ||||
Net Income | 206.3 M | ||||
Cash And Equivalents | 708.6 M | ||||
Cash Per Share | 10.21 X | ||||
Total Debt | 1.45 B | ||||
Debt To Equity | 3.34 % | ||||
Current Ratio | 4.69 X | ||||
Book Value Per Share | 10.48 X | ||||
Cash Flow From Operations | 145.4 M | ||||
Earnings Per Share | 2.93 X | ||||
Market Capitalization | 12.19 B | ||||
Total Asset | 2.59 B | ||||
Retained Earnings | (378 M) | ||||
Working Capital | 1.13 B | ||||
Current Asset | 190.76 M | ||||
Current Liabilities | 65.16 M | ||||
About Insulet Performance
To evaluate Insulet Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Insulet generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Insulet Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Insulet market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Insulet's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 273.55 | 287.22 | |
Return On Tangible Assets | 0.08 | 0.09 | |
Return On Capital Employed | 0.10 | 0.11 | |
Return On Assets | 0.08 | 0.08 | |
Return On Equity | 0.28 | 0.30 |
Things to note about Insulet performance evaluation
Checking the ongoing alerts about Insulet for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Insulet help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Insulet generated a negative expected return over the last 90 days | |
Over 100.0% of the company shares are owned by institutional investors | |
Latest headline from zacks.com: Abbott Q1 Earnings Beat Estimates, Margins Contract |
- Analyzing Insulet's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Insulet's stock is overvalued or undervalued compared to its peers.
- Examining Insulet's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Insulet's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Insulet's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Insulet's stock. These opinions can provide insight into Insulet's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.043 | Earnings Share 2.93 | Revenue Per Share 24.331 | Quarterly Revenue Growth 0.379 | Return On Assets 0.0609 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.